连日来，普洛药业同步亮相美国ChemOutsourcing、BioPacific及欧洲Nordic Life Science Days（NLS Days）三大行业展会，通过北美、欧洲多区域、多平台联动，集中展示公司在CDMO领域的技术平台、产能体系与合规能力，并与北美、欧洲多家药企和创新团队开展对接交流。
本次参展不是单点参展，而是普洛药业深度对接全球医药创新资源，稳步推进全球化CDMO布局的一次集中呈现。公司依托美国波士顿、上海浦东、浙江横店三大CDMO研发中心，持续面向全球创新药客户提供从工艺开发、放大生产到商业化制造的一站式服务，进一步夯实“技术、网络、人才”协同的国际化服务能力。
PART.01
深耕北美创新高地，展示CDMO全链条服务能力
北美是全球生物医药创新核心阵地，汇聚了众多顶尖药企与新锐科创企业，ChemOutsourcing、BioPacific正是当地极具影响力的医药产业交流盛会。本次北美参展由普洛药业高级副总经理、CDMO事业部总经理蔡磊携公司BD团队参加，重点展示普洛药业全链条CDMO研发生产服务，以及绿色合成、连续流化学、生物催化等特色技术平台与产业化落地成果。
BioPacific
ChemOutsourcing
在BioPacific展会现场Lunch & Learn环节，普洛药业CDMO事业部副总经理李睿作主题分享。他表示，随着创新药研发难度提升、分子复杂度增加，药企对CDMO合作伙伴的需求已从基础代工转向更强调科学性、敏捷性和可靠性的CMC合作能力。普洛药业CDMO依托波士顿、上海、横店三位一体研发网络及欧洲办事处，围绕技术、网络、人才协同，搭建覆盖连续流、多肽、ADC、PROTAC等方向的端到端服务体系，凭借以“快响应、稳合规、低成本”的服务能力，帮助全球客户推进创新药产业化。
展会期间，普洛药业团队与多家北美药企、Biotech企业围绕工艺开发、产能配套、项目推进和长期合作等议题开展一对一深度洽谈对接。凭借公司成熟的技术平台、完善的全球合规体系和稳定的生产能力，获得了参会客户的高度关注，并达成了多项初步合作意向，进一步拓展公司在北美创新药市场的合作空间。
PART.02
融入欧洲核心市场，提升CDMO全球市场竞争力
NLS Days是欧洲生物医药领域具有影响力的专业展会，聚焦创新药CMC工艺、供应链优化与产业合规，汇聚北欧及欧洲本土制药企业、研发机构和产业链服务商，是区域内高效的技术交流与商务对接平台。
值得一提的是，本次展会是普洛药业首次亮相并独立设展参与NLS Days。作为丹麦-瑞典跨境生命科学产业集群Medicon Valley Alliance（MVA）会员单位，普洛药业长期深耕欧洲市场，拥有稳定的客户基础和本地服务资源。本次参展，公司进一步依托MVA产业平台，加强与北欧及欧洲生物医药核心圈层的交流，提升欧洲市场服务能力。
近年来，普洛药业持续推进欧洲市场布局，已在德国法兰克福设立全资子公司普洛欧洲有限公司，并聘请Michael Stanek博士出任CDMO事业部高级副总经理兼APELOA EUROPE GmbH总经理，统筹欧洲区域运营、全球CDMO业务拓展，跨国团队及供应链管理，进一步强化欧洲本地化运营能力，提升公司CDMO全球市场竞争力。
此次同步亮相欧美三展，是普洛药业推进国际化战略、提升全球CDMO服务能力的一次具体实践。下一步，公司将持续夯实技术平台、产能体系、合规能力和全球响应能力，深耕北美、欧洲等核心海外市场，以高品质、更稳定、可信赖的CDMO服务支持全球创新药高效产业化，持续释放国际化发展新动能。
Apeloa Showcases Global CDMO Capabilities at Three Major U.S. and European Industry Events
Apeloa Pharmaceutical recently participated in three major industry events—ChemOutsourcing and BioPacific in the United States and Nordic Life Science Days (NLS Days) in Europe. Through this multi-regional, multi-platform presence, the company highlighted its CDMO technology platforms, manufacturing capacity, and compliance capabilities , while engaging with pharmaceutical companies and innovative teams across North America and Europe.
The events were part of Apeloa’s broader effort to connect with global pharmaceutical innovation resources and steadily advance its global CDMO strategy. Leveraging its three major CDMO R&D centers in Boston, Shanghai Pudong, and Hengdian, Zhejiang, Apeloa provides global innovative drug customers with one-stop services from process development, scale-up, to commercial manufacturing. This intergrated network further strengthens the company’s international service capabilities through the synergy of technology, network, and talent.
Expanding Presence in North America’s Innovation Hub
North America is a core hub for global biomedical innovation, home to leading pharmaceutical companies and emerging biotech startups. ChemOutsourcing and BioPacific are among the region’s most influential industry events. Apeloa’s North American participation was led by George Cai, Senior Vice President, and General Manager of CDMO Business Unit, together with the company’s BD team. The team showcased Apeloa’s full-chain CDMO R&D and production services, as well as its distinctive technology platforms, including green synthesis, continuous flow chemistry, and biocatalysis, along with their industrial applications.
BioPacific
ChemOutsourcing
At the Lunch & Learn session at BioPacific, Victor Li , Vice President of CDMO Business Unit, delivered a presentation. He noted that as innovative drug R&D becomes more challenging and molecular complexity increases, pharmaceutical companies are seeking CDMO partners that offer not only contract manufacturing but also stronger scientific rigor, agility, and reliability in CMC collaboration. Relying on its integrated R&D network across Boston, Shanghai, and Hengdian and its European office, Apeloa’s CDMO businesshas built an end-to-end service system covering Flow Chemistry, Peptides, ADCs, PROTACs, and other modalities. With capabilities centered on rapid response, reliable compliance, and cost efficiency, Apeloa helps global customers advance the industrialization of innovative drugs.
During theevents, Apeloa’s team held one-on-one discussion with a number of North American pharmaceutical and biotech companies on process development, capacity support, project advancement, and long-term cooperation. The company’s mature technology platforms, comprehensive global compliance system, and stable production capacity drew strong interest from participating companies and led to several preliminary cooperation opportunities, further expanding its presence in the North American innovative drug market.
Strengthening CDMO Competitiveness ini Europe’s Core Market
NLS Days is an influential professional eventin Europe’s biomedical sector, focusing on CMC processes for innovative drugs, supply chain optimization, and industry compliance. It brings together Nordic and European pharmaceutical companies, R&D institutions, and industry chain service providers, serving as an efficient platform for technical exchange and business matchmaking.
Notably, this was Apeloa’s first independent exhibition at NLS Days. As a member of Medicon Valley Alliance (MVA), a cross-border Danish-Swedish life science cluster, Apeloa has long been active in the European market and has established a stable customer base and local service resources. At NLS Days, the company further leveraged the MVA platform to strengthen exchanges with key players inNordic and European biomedicine and enhance its service capabilities in the European market.
In recent years, Apeloa has continued to expand its European market presence. The company has established a wholly owned subsidiary, APELOA EUROPE GmbH, in Frankfurt, Germany, and appointed Dr. Michael Stanek as Senior Vice President of the CDMO Business Unit and General Manager of APELOA EUROPE GmbH., Dr. Stanek oversees European operations, global CDMO business development, and cross border team and supply chain management, further strengthening Apeloa’s localized operations in Europe and enhancing its global competitiveness in CDMO services.
Apeloa showcases at three major U.S. and European events reflects the company’s commitment to its internationalization strategy and its efforts to enhance global CDMO service capabilities. Looking ahead, Apeloa will continue to strengthen its technology platforms, manufacturing capacity, compliance capabilities, and global response capabilities. The company will deepen its presence in core overseas markets such as North America and Europe, supporting the efficient industrialization of global innovative drugs with high-quality, reliable, and trustworthy CDMO services, while further driving its international growth.